Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
NCT00831974 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2018-12-11
Summary
This is a 12 weeks study aimed at assessing the safety and efficacy of 2 doses of AB1010 in patients suffering from indolent systemic mastocytosis with handicap.
Conditions
- Mastocytosis
Interventions
- DRUG
-
masitinib (AB1010)
3 mg/kg/day
- DRUG
-
masitinib (AB1010)
6 mg/kg/day
Sponsors & Collaborators
-
AB Science
lead INDUSTRY
Principal Investigators
-
Olivier Lortholary, MD, PhD · Hôpital Necker, Paris, France
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-10-31
- Primary Completion
- 2007-02-28
More Related Trials
-
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
NCT00003123 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
NCT01700335 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes
NCT01571648 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
NCT01201811 ·Status: COMPLETED ·Phase: PHASE4
-
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
NCT01873703 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
NCT02014051 ·Status: COMPLETED ·Phase: PHASE1
-
Azacitidine in Treating Patients With Myelofibrosis
NCT00381693 ·Status: TERMINATED ·Phase: PHASE2
-
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
NCT02002936 ·Status: COMPLETED ·Phase: PHASE1
-
Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
NCT02000154 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
NCT00782067 ·Status: COMPLETED ·Phase: PHASE2
-
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
NCT02530619 ·Status: UNKNOWN ·Phase: NA
-
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
NCT06664970 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
NCT00384956 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
NCT01908387 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT02543879 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia
NCT05504408 ·Status: RECRUITING
-
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
NCT01381809 ·Status: COMPLETED ·Phase: PHASE3
-
Nilotinib Plus Pegylated Interferon-α2b in CML
NCT01866553 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
NCT01435720 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
NCT00047190 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
NCT01735955 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
NCT02281084 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
NCT02167360 ·Status: WITHDRAWN ·Phase: PHASE2
-
Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis
NCT00391014 ·Status: COMPLETED ·Phase: PHASE2